MOUNTAIN VIEW, California United States.

-- Drug developer Vivus Inc. commented on Thursday, that the FDA (Food and Drug Administration) will make a decision regarding its new proposed erectile dysfunction medication avanafil by April 29, 2012.

 The FDA  have accepted the new application for marketing approval filed by Vivus on the 30^th of June. Vivus owns the worldwide intellectual property rights to avanafil excluding some Asian Pacific Rim countries.

 Vivus shares fell 34 cents, or 4.1 percent, to $8 on Thursday in a spell of early trading. The stock further declined 9 cents to $7.91, in trades that were made after hours.

 Avanafil is being touted as a treatment of erectile dysfunction by Vivus, who are following in the footsteps of Pfizer (Viagra) and Lily (Cialis), who both manufacture treatments for erectile dysfunction.

 It is estimated the 40% of men over 40 suffer some form of erectile dysfunction.